Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > Obituaries > Gordon McVie 1945–2021: a lifetime dedicated to defeating cancer
  • Obituaries

Gordon McVie 1945–2021: a lifetime dedicated to defeating cancer

  • 22 January 2021
  • Adriana Albini
Gordon McVie 1945–2021: a lifetime dedicated to defeating cancer
Total
18
Shares
18
0
0
0
0

Gordon McVie passed away on January 20th after a lifetime of pioneering contributions to the cause of defeating cancer: as clinician, researcher, manager, advocate and educator. He was a formidable presence on the UK and European stage, driven by a conviction that science can and will defeat cancer; quick to spot and embrace new opportunities; and with a talent for enthusing not just colleagues, but crucially the public and policy makers. His dedication to research, his incredible energy and his breadth of knowledge stemmed from his belief that clinicians and researchers should put cancer patients at the centre of everything they do.

Our readers may know him best for his work as an educator. He was an early adopter of digital technology, welcoming the opportunities offered by the internet to democratise access to the most up-to-date medical and scientific information. In 2007, together with Umberto Veronesi he co-founded ecancer, a web-based organistion that aims to raise the standards of care for cancer patients across the world through education freely accessible to all. McVie quickly became a familiar figure at all the big cancer conferences, grabbing presenters and opinion leaders to take their turn in front of the ecancertv camera to deliver their succinct take on important developments in their fields.

ecancermedicalscience, a cancer journal focused on under-resourced communities, is one of the few peer reviewed open access journals that does not exclude authors who cannot afford to pay a publication fee ‒ something McVie counted among his greatest achievements.

But it was his time leading the work of the UK’s great cancer research charities that may be McVie’s most lasting legacy. In 1989 McVie was appointed Scientific Director ‒ and seven years later Director General ‒ of the Cancer Research Campaign, one of the forerunners of Cancer Research UK. During his time there, more than 60 new drugs were taken from laboratory to clinical trial, including carboplatin, temozolomide, olaparib and abiraterone.

He brought with him the experience of nine years spent in his previous post as Clinical Research Director of the National Cancer Institute of the Netherlands, where he had established a drug development laboratory, and a phase I and II clinical research unit, making full use of emerging molecular biology techniques. Under his leadership, clinical trials run by the CRC network, which were located in academic hospitals across the UK, were all expected to include biological studies. McVie also initiated the policy of involving patients on clinical trials committees, in the face of a certain level of early resistance. He brought in external international specialists to audit the work of every unit on a regular basis, which not only benefited the quality of the work, but also developed highly productive relationships with oncology leaders in the US and across the globe. 

It was his role as an advocate for cancer, however, that made him a familiar face in the British media, enthusing over the prospects for defeating cancer, berating politicians for failing to do more… and when the opportunity arose, helping push through policies that transformed the organisation of cancer care and clinical research, and turbo charged participation rates in cancer clinical trials.

That opportunity came with the election of the Blair government, in 1997. Responding to very public charges that Britain was falling behind and needed to seriously upgrade its cancer capacity, Blair decided to make cancer a flagship policy area. Together with Peter Selby and others, McVie argued the case that the quality of patient care is better in centres that were involved in clinical research. Linking research to outcomes that mattered to the electorate helped persuade the government to invest in modern facilities and equipment badly needed by the network of CRC funded clinical trials units. A major upgrade of the country’s clinical research capabilities saw the creation of the National Cancer Research Network and the National Cancer Research Institute (originally NTRAC). 

The changes ensured the UK retains its place at the cutting edge of the global cancer research effort, and resulted in clinical trial participation quadrupling over the following decade, to reach one in every six cancer patients. But it also saw the end of the CRC, which in 2002 completed a merger with the Imperial Cancer Research Fund to become today’s Cancer Research UK. The merger brought together two of the world’s largest charities – CRCs income had doubled under McVie’s leadership to more than £100 m ‒ ending an unhelpful competition and and outdated separation between the basic and clinical aspects of cancer research. He left the organisation shortly after.

During his time at the CRC McVie continued to be very active on the international scene. He was president of the European Organisation for Research and Treatment of Cancer between 1994 and 1997. Over the course of his career he served on several committees, including the American Association for Cancer Research and the American Society of Clinical Oncology, and the boards of the National Cancer Institutes of France, Italy and the Netherlands. 

In 2004 McVie joined the European Institute of Oncology, in Milan, as Senior Consultant in Clinical Research. He set up a clinical research unit to test new molecules and devices, and developed relations between the institute ‒ a relatively newcomer on the scene ‒ and other leading cancer centres throughout the world.

From 2007 onwards much of his time was taken with his work at ecancer, but he continued to be active in research and drug development as a visiting professor at King’s College London.

Gordon McVie’s infectious optimism about the prognosis for beating cancer could occasionally land him in the line of fire, such as with an editorial in The Lancet (2000) “Overoptimism about cancer”, which took issue with a recent statement by McVie that cancer would be beaten in the lifetime of his sons.

McVie never stopped striving to make that a reality, writing in his LinkedIn profile:

“Forty years in cancer clinical research and people still dying in their thousands. I’d like a better epitaph than that so I’m still following my curiosity genotype, arranging marriages between lab and clinical scientists, and communicating globally online as founding editor of ecancer.org.”

Whether his prediction regarding the death of cancer comes true or not, only time will tell. His contribution to developing the organisations and the people involved in the cancer research effort has certainly increased the chances that it might.

The world loses a charismatic figure in oncology and a great medical personality and a kind and generous man.

A profile of Gordon McVie was published in 2002, in a Cover Story for issue 1 of Cancer Futures, the forerunner to Cancer World.

Total
18
Shares
Share 18
Tweet 0
Share 0
Share 0
Share 0
Adriana Albini

Adriana Albini is scientific collaborator at the European Institute of Oncology (IEO) in Milan, Professor of General Pathology at the Milan Bicocca University, she has been deputy Chief of Genoa Cancer Center and Head of Research Department of Reggio Emilia Cancer Center and Scientific Director of MultiMedica Onlus.

Previous Article
  • Patient’s Voices
  • Voices

From the New Yorker: What Cancer Takes Away

  • 22 January 2021
  • Anne Boyer
View Post
Next Article
  • News

Therapy targeting androgen receptors opens new chapter for hormone driven breast cancers

  • 27 January 2021
  • Janet Fricker
View Post
You May Also Like
View Post
  • Obituaries

Michael Sporn: A pioneer in prevention and a unique and special friend

  • Adriana Albini
  • 4 November 2022
View Post
  • Obituaries

Peter Boyle: a high-impact epidemiologist with contagious dreams

  • Anna Wagstaff
  • 5 August 2022
View Post
  • Obituaries

Louis Denis: one of urology’s most influential and patient-facing physicians

  • Simon Crompton
  • 30 August 2021
View Post
  • Obituaries

Michael Peckham – the artist-oncologist who helped shape our world

  • Anna Wagstaff
  • 23 August 2021
View Post
  • Obituaries

In memoriam Louis Denis

  • Editorial Staff
  • 11 August 2021
View Post
  • Obituaries

Bella Kaufman: a rare combination of humanity and morality

  • Anna Wagstaff
  • 24 June 2021
View Post
  • Obituaries

Angelo Di Leo leaves a living legacy of quality care and research excellence

  • Anna Wagstaff
  • 14 June 2021
View Post
  • Obituaries

José Baselga: A giant of medical oncology

  • Marc Beishon
  • 26 March 2021

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Study highlights need to reanalyse genomics and genetics of metastatic tumours
    • 27 January 2023
  • Current cervical cancer screening paradigm fails older women
    • 26 January 2023
  • Call-to-arms for Europe to provide essential paediatric anti-cancer medicines
    • 9 January 2023
  • Exercise-stimulated myokine production can extend survival in advanced prostate cancer
    • 9 January 2023
  • Five San Antonio take-aways to improve care of breast cancer patients
    • 16 December 2022
Article
  • The cancer patients still struggling to access drugs in the wake of anti-corruption reforms
    • 27 January 2023
  • Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access
    • 26 January 2023
  • Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions
    • 12 January 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • AI in Genomics and Reporting for Clinical Practice
    • 26 January 2023
  • Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care
    • 23 January 2023
  • AI application in diagnosis
    • 11 January 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.